Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients

Abstract

Background: Breast cancer is a heterogeneous disease that represents a major public health problem. The immunohistochemical determination of breast cancer subtypes with regard to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) status can contribute to improved selection of therapy and patientcare. The purpose of this study was to determine the prevalence of the molecular breast cancer subtypes and to assess their associations with classical clinicopathologic parameters for better therapeutic decisions in women with breast cancer in the Ivory Coast. Materials and Methods: Formalinfixed and paraffin-embedded blocks of patients diagnosed with primary breast carcinoma were subjected to immunohistochemical assay for the assessment of ER/RP and HER2 expression. The one-way analysis of variance evaluated the difference between breast cancer subtypes and mean age of patients. The Chi-square Test was used to compare standard clinicopathologic prognostic parameters with tumor subtypes. Results. Among 302 patients, 57% were premenopausal and 43% were postmenopausal. The invasive ductal carcinoma not otherwise specified (IDC NOS) (82.8%) was the most frequent histological type, and the tumor grade 2 (56%) was predominant followed by grade 3 (20.9%). The proportion of positivity of ER, PR, and HER2 was 56%, 49%, and 15.6%, respectively. Half of patients of this study (51.6%) had luminal A breast tumor type followed by TN (32.1%). Other subtypes were luminal B (10.1% ) and non-luminal HER2+ (6.3%). Conclusions. The findings of the present study are in line with the literature and should assist in management of breast cancer in our country.

Breast cancer in togolese women: immunohistochemistry subtypes

“…In the present study, positive ER immunostaining was found in 54.7% of cases. Our result is similar to that reported by Effi in Ivory Coast [ 23 ]. However, our finding is lower than those reported in western countries [ 5 ] and Asia [ 29 , 30 ].…”

Prevalence of Breast Cancer Intrinsic Subtypes and Its Association with Clinico-Pathological Feature

“…Luminal B like (25.9%) and triple negatives (25.7%) were the commonest variety seen and overall Her2 positivity was seen in 30.1% of the patients. Luminal A-like disease with good prognosis is seen only is 18.3% of the cases which is in contrast to the figures from other areas reported to be 27.1% by Smriti Tiwari et al, 51.6% by Ahoua B Effect et al, Lin Ch 67% and it has been reported to be as high as 74.3% by Ahmed Abdel-Latif [10][11][12][13][14]. Luminal B like was the commonest type seen in our patients, like in Columbian women which were 37.2% [15].…”

Differential Gene Expression in Ductal Carcinoma in Situ of the Breast Based on ERBB2 Status

“…The age of those in the ERBB2-positive group was not significantly different from the other 2 groups. The median age of the control group was significantly younger when compared with the other groups (30.5 years [range, [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40]). Two patients were lost during follow-up, and the remaining patients were followed-up for 23 to 50 months after surgical excision, with an average follow-up time of 41 months.…”

“…13,[23][24][25][26][27][28][29][30][31][32] The natural history, progression, and mechanism underlying DCIS are poorly understood, although several studies have shown that the transition from DCIS to invasive disease is associated with quantitative rather than qualitative differences in gene expression. 2,14,25,33 Biological markers to predict the presence of occult invasive disease or to identify patients at higher risk of developing invasive cancer are needed so that clinicians can better tailor the management of these lesions.…”